Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $3.6 million.

  • Mirum Pharmaceuticals' Interest Expenses rose 55.77% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 52.47%. This contributed to the annual value of $14.3 million for FY2024, which is 525.65% down from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Interest Expenses stood at $3.6 million for Q3 2025, which was up 55.77% from $3.6 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Interest Expenses' 5-year high stood at $5.7 million during Q3 2021, with a 5-year trough of $3.4 million in Q1 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Interest Expenses had a median value of $3.6 million in 2025 and averaged $3.9 million.
  • In the last 5 years, Mirum Pharmaceuticals' Interest Expenses soared by 102417.91% in 2021 and then tumbled by 2992.77% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Interest Expenses (Quarter) stood at $3.8 million in 2021, then grew by 15.75% to $4.4 million in 2022, then dropped by 18.26% to $3.6 million in 2023, then rose by 0.45% to $3.6 million in 2024, then rose by 0.75% to $3.6 million in 2025.
  • Its Interest Expenses stands at $3.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.6 million for Q1 2025.